![130350-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-04/130350-Thumbnail%20Image.png?versionId=w3dG6iWiJ7Jasvugcwrgw.8FSiNaZnFt&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240605/us-west-2/s3/aws4_request&X-Amz-Date=20240605T170724Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=5f6a567148781deda2b2127cea49a69bf03bb9d1363d553f03ee72983f413f09&itok=D7ID6Po8)
The membrane proximal region (MPR, residues 649–683) and transmembrane domain (TMD, residues 684–705) of the gp41 subunit of HIV-1’s envelope protein are highly conserved and are important in viral mucosal transmission, virus attachment and membrane fusion with target cells. Several structures of the trimeric membrane proximal external region (residues 662–683) of MPR have been reported at the atomic level; however, the atomic structure of the TMD still remains unknown. To elucidate the structure of both MPR and TMD, we expressed the region spanning both domains, MPR-TM (residues 649–705), in Escherichia coli as a fusion protein with maltose binding protein (MBP). MPR-TM was initially fused to the C-terminus of MBP via a 42 aa-long linker containing a TEV protease recognition site (MBP-linker-MPR-TM).
Biophysical characterization indicated that the purified MBP-linker-MPR-TM protein was a monodisperse and stable candidate for crystallization. However, crystals of the MBP-linker-MPR-TM protein could not be obtained in extensive crystallization screens. It is possible that the 42 residue-long linker between MBP and MPR-TM was interfering with crystal formation. To test this hypothesis, the 42 residue-long linker was replaced with three alanine residues. The fusion protein, MBP-AAA-MPR-TM, was similarly purified and characterized. Significantly, both the MBP-linker-MPR-TM and MBP-AAA-MPR-TM proteins strongly interacted with broadly neutralizing monoclonal antibodies 2F5 and 4E10. With epitopes accessible to the broadly neutralizing antibodies, these MBP/MPR-TM recombinant proteins may be in immunologically relevant conformations that mimic a pre-hairpin intermediate of gp41.
![130351-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-04/130351-Thumbnail%20Image.png?versionId=tBT5SGBej18LnPsgZCWNj9cuqqy9tSah&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240530/us-west-2/s3/aws4_request&X-Amz-Date=20240530T155452Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=f1561b5b36be3bd89fcc3e1309cd79b4ab4c89d3dc3992aecaa6796863458c19&itok=ijEt79V-)
Viral protein U (Vpu) is a type-III integral membrane protein encoded by Human Immunodeficiency Virus-1 (HIV- 1). It is expressed in infected host cells and plays several roles in viral progeny escape from infected cells, including down-regulation of CD4 receptors. But key structure/function questions remain regarding the mechanisms by which the Vpu protein contributes to HIV-1 pathogenesis. Here we describe expression of Vpu in bacteria, its purification and characterization. We report the successful expression of PelB-Vpu in Escherichia coli using the leader peptide pectate lyase B (PelB) from Erwinia carotovora. The protein was detergent extractable and could be isolated in a very pure form. We demonstrate that the PelB signal peptide successfully targets Vpu to the cell membranes and inserts it as a type I membrane protein. PelB-Vpu was biophysically characterized by circular dichroism and dynamic light scattering experiments and was shown to be an excellent candidate for elucidating structural models.
![130311-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-04/130311-Thumbnail%20Image.png?versionId=qHMde1a9_azrWBw6LMhLxblmGpj1T5VL&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240530/us-west-2/s3/aws4_request&X-Amz-Date=20240530T153726Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=41adb2a374858bed3f69bffdc20ae60b6118ac9b4a692ad1a10cfcb435e6fa33&itok=WBhJHD7-)
![130313-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-04/130313-Thumbnail%20Image.png?versionId=kqD.YDB1VX5uQO57RpUMtuE923xLWhlm&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240530/us-west-2/s3/aws4_request&X-Amz-Date=20240530T153726Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=05ec79073f27c2e53cb226bb4cd4865425dd3116805c5d2eeea0420e1d49b6f1&itok=zdlOjHlD)
![130315-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-04/130315-Thumbnail%20Image.png?versionId=J__qiVF2.nKDjkZMX27cQOuKXATLGXAy&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240530/us-west-2/s3/aws4_request&X-Amz-Date=20240530T153827Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=1ceaecfdf71ea94fe7ee2da22434703b52c8bd38ad31b798ab42f3c6bc63c13a&itok=aBPoEPyH)
![130318-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-04/130318-Thumbnail%20Image.png?versionId=njhRBNM0BKpD1_HhHfyY6Wsc64iBsWhF&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240530/us-west-2/s3/aws4_request&X-Amz-Date=20240530T153827Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=e6cee279f4a2fd00dab3be5e50a0baa2ff7102f6ee11c27f25757be4ef9af1b9&itok=okv7UB4w)
![132806-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-05/132806-Thumbnail%20Image.png?versionId=MzdW99LczDSR5aFhokMmLNEVTqSJKxKn&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240614/us-west-2/s3/aws4_request&X-Amz-Date=20240614T023631Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=2cc33709cd3ceb072f144620d16e283cb0c8eeeab215804d545383340774fdc1&itok=DzUkngtc)
![134334-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-05/134334-Thumbnail%20Image.png?versionId=7WkaIwtWbPSJgUKmlnrZNmM_xumTvU7E&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240614/us-west-2/s3/aws4_request&X-Amz-Date=20240614T023631Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=3acb023895c339f2e22585ea79ece436aea95e124a22fef0688a178a6b64ee4c&itok=36K1Wvf9)
![134727-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-05/134727-Thumbnail%20Image.png?versionId=gllYvCTaqN4TXvlPY_Gd7VeePkhKvTIs&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240614/us-west-2/s3/aws4_request&X-Amz-Date=20240614T023631Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=74a8be88f78d7fdfbc76c80842faad59301fea264cf4608b9f7f9ff9e9f5ff8e&itok=sJoEvjrm)
An electric field can be applied to a microfluidic device in order to stop particle flow. Electroosmosis, electrophoresis, and dielectrophoresis act on the particles in different directions in the microfluidic channel, and when these forces create zero net force, the particle stops in the channel. The goal of the performed experiments is to investigate whether hydrostatic pressure generated by a syringe pump could help concentrate these particles and separate them from other contents. Introducing precise, adjustable hydrostatic pressure from the syringe pump provides another mechanism for controlling particle behavior. A microfluidic channel was crafted into a device connected to a syringe pump, and videos of 1 µm silica particles in the device were recorded under a microscope in order to show that samples could be infused into the device and concentrated or captured at a specific location in the channel using hydrostatic pressure. Capture of the particles occurred with and without controlled hydrostatic pressure, but these events occurred somewhat consistently at different voltages. In addition, particle movement in the channel with the syringe pump off was originally attributed to the electrokinetic forces. However, when compared to experiments without the syringe pump connected to the device, it became evident that the electrokinetic forces should have moved the particles in the opposite direction and that, in actuality, there is an inherent pressure in the device also affecting particle movement even when the syringe pump is not turned on.